- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03832361
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
April 25, 2023 updated by: Alessandro Santin
A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Study Overview
Detailed Description
This study will enroll patients with persistent or recurrent FRα-positive uterine serous carcinoma (pure or mixed), Grade 3 endometrial adenocarcinoma, or carcinosarcoma with high grade serous or Grade 3 endometrioid components.
All patients must have measurable disease.
The primary objective of the study is to assess the activity of IMGN853 as measured by objective response rate (ORR).
The secondary objectives are to assess the duration of overall survival (OS), progression-free survival (PFS) and durable disease control rate (DDCR), as well as the safety profile of IMGN853 in endometrial carcinoma patients.
Exploratory/correlative objectives are to correlate ORR, PFS, and OS with the level of folate receptor α expression and explore use of circulating tumor (ct) DNA as a biomarker for disease response and compare its performance to cancer antigen 125 (CA-125).
All enrolled patients will receive IMGN853 at a dose of 6 mg/kg administered intravenously once every 3 weeks until unacceptable toxicity or progression of disease requiring discontinuation of treatment.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Smilow Cancer Hospital at Yale New Haven
-
Contact:
- Alessandro D Santin, M.D.
- Phone Number: 203-737-4450
- Email: alessandro.santin@yale.edu
-
Principal Investigator:
- Alessandro Santin, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Radiologically confirmed (ie, CT scan and/or MRI) persistent or recurrent endometrial cancer
- Patients must have one of the following pathologically documented, definitively diagnosed tumor types: Uterine serous carcinoma (Pure or Mixed), Grade 2 or Grade 3 endometrial adenocarcinoma, Carcinosarcoma with high grade serous or Grade 2/3 endometrioid components, or clear cell carcinoma (Pure or Mixed).
- Have measurable disease
- FRα-positive tumor expression as defined in the protocol
- Have at least one "target lesion" to be used to assess response as defined by RECIST v1.1
- Patients must have received prior treatment with ≤ 3 prior lines of therapy for recurrent disease; hormonal agents are not considered a line of therapy; prior treatment with folate receptor-targeting investigational agents is not allowed
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Time from prior therapy: Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter; Radiotherapy: wide-field radiotherapy completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
- Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy
- Patients must have adequate hematologic, liver and kidney function as defined in the protocol
- Women of child bearing potential (WCBP), must agree to use effective contraceptive methods during study treatment and for at least twelve weeks after the last dose of IMGN853
- WCBP must have a negative pregnancy test within 4 days prior to the first dose of study treatment
- At time of initial surgery, patient may have either been optimally or suboptimally debulked
- Have signed the informed consent form, and willing to adhere to the study visit schedule and other protocol requirements
- ≥ 18 years of age
Exclusion Criteria:
- Active or chronic corneal disorder
- Serious concurrent illness or clinically-relevant active infection as defined in the protocol
- Clinically-significant cardiac disease such as recent myocardial infarction (≤ 6 months prior to day 1), unstable angina pectoris, uncontrolled congestive heart failure, uncontrolled hypertension, prior history of hypertensive crisis or hypertensive encephalopathy, uncontrolled cardiac arrhythmias, clinically-significant vascular disease, severe aortic stenosis, clinically significant peripheral vascular disease, or cardiac toxicity following prior chemotherapy
- History of neurological conditions
- History of hemorrhagic or ischemic stroke within the last 6 months
- History of cirrhotic liver disease
- Previous clinical diagnosis of non-infectious pneumonitis
- Prior hypersensitivity to monoclonal antibodies
- Women who are pregnant or breast feeding
- Carcinomatous meningitis, untreated central nervous system (CNS) disease or symptomatic CNS metastasis
- History or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment
- Required used of folate-containing supplements (e.g. folate deficiency)
- Has a known additional malignancy that is progressing or required active treatment within 3 years of first dose of study treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMGN853
IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W)
|
IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: 5 Years
|
Objective response rate (complete response and partial response rates) by RECIST 1.1 criteria of mirvetuximab soravtansine in patients with folate receptor α-positive persistent or recurrent endometrial cancer
|
5 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of overall survival (OS)
Time Frame: 5 Years
|
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.
|
5 Years
|
Duration of progression free survival (PFS)
Time Frame: 5 Years
|
Progression-free survival is defined as the duration of time from study entry to time of progression, death, or the date of last contact, whichever occurs first.
|
5 Years
|
Durable disease control rate (DDCR)
Time Frame: 5 Years
|
The percentage of patients who have achieved complete response, partial response, and stable disease.
|
5 Years
|
Safety profile of mirvetuximab soravtansine (IMGN853) in endometrial cancer patients (adverse events as assessed by CTCAE v5.0)
Time Frame: 5 Years
|
Incidence of treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
|
5 Years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 15, 2020
Primary Completion (Anticipated)
October 1, 2023
Study Completion (Anticipated)
October 1, 2028
Study Registration Dates
First Submitted
February 4, 2019
First Submitted That Met QC Criteria
February 5, 2019
First Posted (Actual)
February 6, 2019
Study Record Updates
Last Update Posted (Actual)
April 27, 2023
Last Update Submitted That Met QC Criteria
April 25, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Endometrial Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Maytansine
Other Study ID Numbers
- 2000023841
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Batman Training and Research HospitalEskisehir Osmangazi UniversityCompletedGynecologic Cancer | Endometrial Cancer Stage
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAdvanced Endometrial CancerChina
-
Novartis PharmaceuticalsCompletedAdvanced Endometrial CancerBelgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
-
Samsung Medical CenterRecruitingEndometrial Cancer Stage IKorea, Republic of
-
Duke UniversityDuke Cancer InstituteCompleted
-
Far Eastern Memorial HospitalCompletedOutcome of Endometrial CancerTaiwan
-
Rambam Health Care CampusCompletedSerous Papillary Endometrial CancerIsrael
-
Masonic Cancer Center, University of MinnesotaCompletedCervical Cancer | Ovarian Cancer | Uterine Endometrial CancerUnited States
Clinical Trials on IMGN853
-
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.RecruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal CancerChina
-
Duke UniversityNational Comprehensive Cancer NetworkWithdrawnBreast Cancer Triple NegativeUnited States
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLC; ImmunoGen, Inc.RecruitingEndometrial CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States
-
ImmunoGen, Inc.RecruitingFallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Ovarian CancerUnited States, Spain, United Kingdom, Belgium, Canada, Georgia
-
University of Alabama at BirminghamRecruitingOvarian Cancer | Primary Peritoneal Cancer | Fallopian TubeUnited States
-
ImmunoGen, Inc.Active, not recruitingOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States, France, Belgium, Spain, Ireland, Italy, Australia, Canada
-
Shattuck Labs, Inc.Enrolling by invitationOvarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal CarcinomaUnited States, United Kingdom, Spain, Canada
-
ImmunoGen, Inc.CompletedFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal CancerUnited States, Belgium, Spain, Israel, Australia, Ireland, Germany, Italy, Bulgaria, Czechia, Poland